GLP-1 denials in California external review
Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda. The California DMHC record publishes a separate cohort of external-review decisions for each of these GLP-1 drugs — from 20 to 675 decisions each. Independent physician reviewers overturned the plan’s denial in 67.6–95% of them, depending on the drug. Those historical results describe cases that reached this California program; they do not predict an individual appeal.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY
EACH ROW BELOW IS ITS OWN COHORT OF PUBLISHED DECISIONS. ONE DECISION CAN NAME MORE THAN ONE OF THESE, SO THE ROWS OVERLAP AND MUST NOT BE ADDED TOGETHER — WE PUBLISH NO COMBINED TOTAL, BECAUSE THE DEDUPLICATED SET-UNION FIGURE IS NOT IN THE SOURCE AGGREGATES.
The record, drug by drug
| Drug | FDA-approved for | Decisions | Overturned |
|---|---|---|---|
| Wegovy | Chronic weight management | 675 | 88.7% |
| Zepbound | Chronic weight management | 657 | 91.5% |
| Mounjaro | Type 2 diabetes | 170 | 68.8% |
| Ozempic | Type 2 diabetes | 148 | 67.6% |
| Wegovy Solution Auto-injector | See Wegovy | 20 | 95% |
| Saxenda | Chronic weight management | 51 | 86.3% |
Why GLP-1 denials happen
GLP-1 receptor agonists are expensive, effective, and in staggering demand — which makes them the exact profile of drug that plans build denial machinery around. Nearly every GLP-1 denial letter falls into one of six patterns, and each has a known counter.
Formulary exclusion of weight-loss drugs
Many plans — especially self-funded employer plans — exclude the entire anti-obesity medication category from the formulary. The letter says “not a covered benefit.” This is the hardest pattern, but not a dead end: appeals dispute whether the exclusion's actual language reaches your prescription, and newer indications (cardiovascular risk reduction, sleep apnea) often fall outside what the exclusion was written to cover.
“Lifestyle” or “cosmetic” exclusions
Some denials classify weight management itself as cosmetic. Obesity is a diagnosed chronic disease with its own ICD codes, and the drugs at issue carry FDA approvals for treating it — plus, for Wegovy and Zepbound, approvals for cardiovascular-risk and sleep-apnea indications that no honest reading calls cosmetic. Reviewers see through this framing, which is part of why overturn rates run so high.
Step therapy
The plan wants documented failure of cheaper options first — a structured diet-and-exercise program, an older weight-loss drug, or (for diabetes) metformin and other preferred agents. Most step-therapy denials are documentation failures, not clinical ones: the trials happened, but nobody put them in the prior-auth request.
BMI and comorbidity documentation requirements
Plan criteria typically track the FDA label's BMI framework, requiring chart-documented BMI and, at lower thresholds, a weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea. Denials cite what the chart doesn't show — which an appeal can simply supply.
Quantity limits and dose titration
GLP-1s are titrated stepwise to a maintenance dose, and shortage-era substitutions scrambled many regimens. That produces refill and quantity-limit denials that have nothing to do with medical necessity and everything to do with pharmacy plumbing. These resolve through exception requests and appeals at very high rates.
Indication mismatch
The single most preventable GLP-1 denial: a diabetes-labeled drug (Ozempic, Mounjaro) prescribed for weight loss, or coverage criteria applied to the wrong indication. The same molecules carry weight-management approvals under different names — details below, because this is where the data gets interesting.
Same molecule, different label: the cross-indication problem
Two molecules power almost this entire drug class, and each is sold under two names with different FDA approvals:
Insurers know this map cold, and the published review outcomes show exactly how much the label matters. When the weight-management-labeled drugs were denied for obesity, reviewers overturned the plan 92.4% of the time for Zepbound (591 decisions) and 89.4% for Wegovy (633 decisions). When the diabetes-labeled versions were requested for obesity instead, the numbers drop — 75% for Ozempic and just 58.6% for Mounjaro, even though Mounjaro denials for its on-label type 2 diabetes indication were overturned 78% of the time. The California record shows materially different historical results by indication. If the clinical goal is weight management, Wegovy is the on-label semaglutide product and Zepbound is the on-label tirzepatide product; the prescription and appeal record should state the actual diagnosis and approved indication without recasting the clinical facts.
The newer indications also quietly demolish the most common denial rationale. A plan that dismisses semaglutide as a “lifestyle drug” has to contend with Wegovy’s FDA approval for reducing cardiovascular events in adults with heart disease. A plan calling tirzepatide cosmetic has to explain Zepbound’s approval for obstructive sleep apnea. If you qualify for one of these indications, lead with it.
What overturned GLP-1 decisions address
The overturned decisions in the California corpus show recurring evidence patterns, not a guaranteed playbook. The first move is diagnostic: figure out whether you’re fighting a medical-necessity denial(the plan covers the drug class but says you don’t qualify) or a benefit-exclusion denial(the plan says the category isn’t covered at all). They’re different fights.
Against medical-necessity denials: meet the criteria point-by-point
Request the plan's specific clinical criteria. Then have your treating physician address each applicable criterion directly: documented BMI history, weight-related comorbidities, A1C and diagnosis for the diabetes drugs, and the clinical goal of therapy. This lets a reviewer compare the complete chart with the stated basis for denial.
Against step-therapy denials: document the failures
List every prior attempt with specifics — program or drug, dates, duration, outcome, side effects. If the plan offers a step-therapy exception, use its required process and deadline. A prescriber statement can document why alternatives failed or are clinically inappropriate; the governing rule depends on the plan and jurisdiction.
Against exclusions: attack the language, not the policy
Make the plan quote the exact exclusion text. Then test it: does it reach a drug prescribed for cardiovascular risk reduction? For obstructive sleep apnea? For a chronic disease with its own diagnosis codes? Exclusions written to block “cosmetic weight loss” often don't cleanly cover what was actually prescribed — and ambiguity gets argued against the drafter.
Always: the treating-physician letter
The single highest-leverage document in the packet. It should tie the patient's chart to the plan's criteria, state the FDA-approved indication being treated, recount prior failures, and say plainly why this drug, at this dose, now.
Who regulates your plan changes the fight
The same Wegovy prescription can be an easy approval under one plan and a categorical exclusion under another, because GLP-1 coverage is decided plan by plan — and the rules that police the plan depend on who regulates it.
- Employer coverage is usually a self-funded plan governed by federal ERISA rules. The employer — not the insurer whose logo is on the card — chose whether to buy the weight-loss drug benefit, and appeals run through a federally required internal process followed by independent external review. HR benefit-exception requests are a real parallel track here. ERISA appeal rights.
- ACA marketplace and other state-regulated plans answer to state insurance law: step-therapy exception statutes, mandated decision deadlines, and the state external-review process that produced the numbers on this page. Marketplace appeal rights.
- Medicaiddrug coverage is set state by state; GLP-1s prescribed for type 2 diabetes are widely covered, while anti-obesity coverage varies with the state’s program. Fair-hearing rights apply to denials. Medicaid appeal rights.
- Medicare Advantagehas its own multi-level appeal ladder: if the plan doesn’t fully rule in your favor, your case is automatically forwarded to an independent reviewer. Medicare Advantage appeal rights.
Identify your plan type before you write a word of the appeal — it determines your deadlines, your reviewer, and which exception statutes you can invoke.
The documentation that decides these cases
Across the overturned decisions, the pattern is consistent: reviewers reverse plans when the record is complete. Before filing, assemble:
- The denial letter itself, plus the plan's clinical criteria for the drug (request them in writing — you are entitled to them).
- Chart-documented BMI history, and for the diabetes drugs, diagnosis codes and A1C values over time.
- Weight-related comorbidities with dates: hypertension, dyslipidemia, sleep apnea, joint disease, fatty liver disease — whatever the chart supports.
- Every prior weight-management or glycemic-control attempt: program names, medications, doses, duration, outcome, side effects.
- A treating-physician letter that walks the plan's criteria point by point and states the FDA-approved indication being treated.
- For sleep-apnea cases: the sleep study. For cardiovascular cases: the cardiac history. Lead with the indication the exclusion can't reach.
Medicare Part D has historically excluded drugs used for weight loss, while covering GLP-1s prescribed for type 2 diabetes. Coverage rules for anti-obesity medication are changing — check your plan’s current formulary and criteria rather than assuming either answer. Medicare Advantage members also have unusually strong appeal machinery: see how Medicare Advantage appeals work.
If the internal appeal fails: external review
Every number on this page comes from California DMHC external review, generally after the plan’s internal appeal process. Other jurisdictions and federal plan programs use different reviewers, eligibility rules, deadlines, and remedies; some plans are outside state external-review authority. Check your appeal rights by plan type and state.
Related reading: prior-authorization denials · “not medically necessary” denials · “not a covered benefit” denials · obesity denial outcomes · all treatments
GLP-1 denial FAQ
Yes. A plan exclusion narrows your arguments but doesn't end them. Appeals challenge whether the exclusion actually applies (Wegovy has a cardiovascular indication and Zepbound a sleep-apnea indication that weight-loss exclusions weren't written to reach), whether the plan quoted real exclusion language, and whether state or federal rules limit the exclusion. In the published California external-review record, the large majority of GLP-1 denials taken to review were overturned.
Ozempic and Mounjaro are FDA-approved for type 2 diabetes. When the diagnosis on the request is obesity rather than diabetes, plans deny for indication mismatch — and reviewers side with plans on off-label weight-loss requests far more often than on diabetes requests. The same molecules are approved for chronic weight management as Wegovy (semaglutide) and Zepbound (tirzepatide); an on-label prescription is a much stronger position.
The pattern across overturned decisions: a treating-physician letter tied to the plan's own criteria, chart documentation of BMI and weight-related comorbidities (or A1C and diagnosis for diabetes drugs), a specific account of prior treatments tried and failed for step-therapy rules, and the FDA-approved indication stated plainly. The reviewed decisions often turn on whether the record addresses the plan's exact criteria.
Medicare Part D has historically excluded drugs used for weight loss, while covering GLP-1s prescribed for type 2 diabetes. Coverage rules for anti-obesity medication are changing — check your specific plan's current formulary and criteria before assuming either answer.
Internal-appeal deadlines are commonly 180 days from the denial notice for employer and marketplace plans, and 60 days for Medicare Advantage — but your denial letter's stated deadline controls, so read it. External-review windows after the internal denial vary by state and plan type. If you're mid-titration or your health is at risk from delay, request an expedited appeal, which compresses the decision timeline to days.
Not necessarily. Many appeals are filed by patients, authorized representatives, and treating clinicians using a letter, supporting records, and the plan's criteria. Legal help can matter in complex or high-value disputes, suspected bad-faith patterns, or litigation after administrative appeals are exhausted.
You may be eligible for an independent external review, but the reviewer, deadlines, eligibility rules, and effect of the decision depend on your plan type and jurisdiction. The statistics on this page are limited to eligible cases completed through California DMHC's Independent Medical Review program.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY